Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 16/20 | 0.64 |
| ▸ | PDE4A | P27815 | 13/20 | 0.64 |
| ▸ | PDE4C | Q08493 | 8/20 | 0.64 |
| ▸ | PDE4D | Q08499 | 8/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2525360 | 0.86 | PDE4B (0.71) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL18595962 | 0.83 | PDE4B (0.71) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL2530691 | 0.81 | PDE4B (0.74) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL10237002 | 0.80 | PDE4B (0.68) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL595819 | 0.79 | PDE4B (1.00) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL5583359 | 0.79 | PDE4B (1.00) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL14734851 | 0.76 | PDE4B (0.67) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL7862589 | 0.76 | PDE4B (0.42) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL15929850 | 0.76 | PDE4B (0.61) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL16478617 | 0.76 | PDE4B (0.79) | PDE4BPDE4APDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3246034-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS | Anacor Pharmaceuticals, Inc. (US) | 2017-11-22 | — | — | EP | disclosed |
| US-20160318955-A1 | Boron-Containing Small Molecules as Anti-Inflammatory Agents | ANACOR PHARMACEUTICALS, INC. | 2016-11-03 | — | — | US | disclosed |
| US-20160318955-A1 | Boron-Containing Small Molecules as Anti-Inflammatory Agents | ANACOR PHARMACEUTICALS, INC. | 2016-11-03 | — | — | US | disclosed |
| US-20160318955-A1 | Boron-Containing Small Molecules as Anti-Inflammatory Agents | ANACOR PHARMACEUTICALS, INC. | 2016-11-03 | — | — | US | disclosed |
| US-9416146-B2 | Boron-containing small molecules as anti-inflammatory agents | ANACOR PHARMACEUTICALS, INC. (US) | 2016-08-16 | — | — | US | disclosed |
| US-9416146-B2 | Boron-containing small molecules as anti-inflammatory agents | ANACOR PHARMACEUTICALS, INC. (US) | 2016-08-16 | — | — | US | disclosed |
| US-9416146-B2 | Boron-containing small molecules as anti-inflammatory agents | ANACOR PHARMACEUTICALS, INC. (US) | 2016-08-16 | — | — | US | disclosed |
| US-20150291629-A1 | Boron-Containing Small Molecules as Anti-Inflammatory Agents | ANACOR PHARMACEUTICALS, LLC | 2015-10-15 | — | — | US | disclosed |
| US-20150291629-A1 | Boron-Containing Small Molecules as Anti-Inflammatory Agents | ANACOR PHARMACEUTICALS, LLC | 2015-10-15 | — | — | US | disclosed |
| US-20150291629-A1 | Boron-Containing Small Molecules as Anti-Inflammatory Agents | ANACOR PHARMACEUTICALS, LLC | 2015-10-15 | — | — | US | disclosed |
| EP-2564857-A1 | Boron-containing small molecules as anti-inflammatory agents | Anacor Pharmaceuticals, Inc. (US) | 2013-03-06 | — | — | EP | disclosed |
| US-20120214765-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS | ANACOR PHARMACEUTICALS, INC. (US) | 2012-08-23 | — | — | US | disclosed |
| US-20120214765-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS | ANACOR PHARMACEUTICALS, INC. (US) | 2012-08-23 | — | — | US | disclosed |
| US-20120214765-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS | ANACOR PHARMACEUTICALS, INC. (US) | 2012-08-23 | — | — | US | disclosed |
| US-8039450-B2 | Boron-containing small molecules as anti-inflammatory agents | ANACOR PHARMACEUTICALS, INC. (US) | 2011-10-18 | — | — | US | disclosed |
| US-8039450-B2 | Boron-containing small molecules as anti-inflammatory agents | ANACOR PHARMACEUTICALS, INC. (US) | 2011-10-18 | — | — | US | disclosed |
| US-8039450-B2 | Boron-containing small molecules as anti-inflammatory agents | ANACOR PHARMACEUTICALS, INC. (US) | 2011-10-18 | — | — | US | disclosed |
| US-20090291917-A1 | Boron-Containing Small Molecules as Anti-Inflammatory Agents | ANACOR PHARMACEUTICALS, INC. (US) | 2009-11-26 | — | — | US | disclosed |
| US-20090291917-A1 | Boron-Containing Small Molecules as Anti-Inflammatory Agents | ANACOR PHARMACEUTICALS, INC. (US) | 2009-11-26 | — | — | US | disclosed |
| US-20090291917-A1 | Boron-Containing Small Molecules as Anti-Inflammatory Agents | ANACOR PHARMACEUTICALS, INC. (US) | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291917-A1 | Boron-Containing Small Molecules as Anti-Inflammatory Agents | NFKBIA, LITAF, CD68 | PDE4B 776/4885PDE4A 1019/4885PDE4C 1729/4885 |
| US-20160318955-A1 | Boron-Containing Small Molecules as Anti-Inflammatory Agents | NFKBIA, LITAF, CD68 | PDE4B 776/4885PDE4A 1019/4885PDE4C 1729/4885 |
| US-20150291629-A1 | Boron-Containing Small Molecules as Anti-Inflammatory Agents | NFKBIA, LITAF, CD68 | PDE4B 776/4885PDE4A 1019/4885PDE4C 1729/4885 |
| US-20120214765-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS | NFKBIA, LITAF, CD68 | PDE4B 776/4885PDE4A 1019/4885PDE4C 1729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.